Armata Pharmaceuticals ARMP 深 滬
已收盤 05-08 16:00:00 美东时间
8.30
-0.850
-9.29%
華盛通- 最 高9.2502
- 今 開9.11
- 成交量 5.08万股
- 最 低 8.30
- 昨 收 9.15
- 總市值 3.05亿
- 52周最高 16.34
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 1.17
- 委 比 0.00%
- 總股本 3669.52万
- 歷史最高 16.34
- 量 比 0.52
- 振 幅 10.38%
- 歷史最低 0.8311
- 每 手 1
- 風險率 3.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advance...
05-07 19:00
Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio
The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail,
05-04 19:07
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: A...
05-04 19:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
03-27 20:10
Armata Pharmaceuticals Q4 EPS $(3.43) Misses $(0.28) Estimate, Sales $1.085M Beat $750.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the analyst consensus estimate of $(0.28) by 1125 percent. This is a 1391.3 percent decrease over losses of $(0.23) per share
03-26 04:29
3 things to look forward to on Monday
U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to minimize the impact of the war on the commodity sector. The benchmark...
03-21 04:57
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
Armata Pharmaceuticals ( ($ARMP) ) just unveiled an update. On March 19, 2026, ...
03-19 19:27
Armata Pharmaceuticals To Delay Announcement Of Q4, FY25 Financial Results; Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment
03-19 19:06
Armata Pharmaceuticals delays Q4 and full-year 2025 results release to March 31, 2026
Armata Pharmaceuticals delays Q4 and full-year 2025 results release to March 31, 2026 Armata said it will delay reporting its fourth-quarter and full-year results for the year ended Dec. 31, 2025, and expects to file its annual report on or before March 31, 2026. The FDA granted AP-SA02 Qualified In
03-19 19:06
